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Sentinel Lymph Node Biopsy in oral squamous cell carcinoma: 
Analysis of error in a cohort of 100 consecutive cases. 
Abstract 
 
Objectives: UK national guidelines (2016) recommend Sentinel Lymph Node Biopsy (SLNB) 
be offered to patients with early oral cancer (T1-T2 N0) where the primary site can be 
reconstructed directly. This study highlights pitfalls that can be avoided in SLNB technique in 
order to further improve outcomes.  
Materials and Methods: Retrospective analysis of 100 consecutive patients was performed.  
Adverse events within the SLNB protocol or poor patient outcomes triggered a root cause 
analysis of the records. 
Results and Discussion: Lymphatic drainage of tracer failed in 2 cases due to procedural 
errors.  Two +SLNB patients developed neck recurrence after completion neck dissection, 
one due to missed micro-metastasis, the other due to extra nodal spread leading to under 
staging and under treatment. Two false negative (FN) cases would not have occurred if all the 
harvested SLN had been histologically analysed according to the SLN protocol.  
Conclusions: The disease specific (96%) and disease free (92%) survivals were above 
expectations for a cohort where 33% had stage 3 disease.  If all harvested nodes had been 
analysed by SLN pathology protocol then 2 out of 3 FN cases would have been detected and 
two deaths potentially avoided. The FN rate would have fallen from 8.3% to 2.7%. The 
overarching message is that minor protocol deviations can result in a detrimental patient 
outcome. 
Introduction 
 
Recent evidence confirms a survival advantage of elective neck dissection (END) over a 
watch and wait policy1 in patients with early oral squamous cell carcinoma (OSCC) and a 
clinically N0 neck. Meta-analysis2-4 demonstrates that sentinel lymph node biopsy (SLNB) 
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can reliably identify early metastasis and restrict neck dissection (ND) to 20-30%5-7 with a 
positive (+) SLNB. United Kingdom guidelines (2016) recommended SLNB is offered to 
patients (T1-T2 N0) with OSCC following the example of Denmark and Holland where it is 
standard8.  
SLNB has a sensitivity and specificity of 79%-87% but a recognised false negative rate (FN) 
of up to 14%5. Reporting positive results is necessary to gain confidence in a technique but 
more informative data is gained in analysing failure. This study undertakes a root cause 
analysis of any adverse event in 100 consecutive SLNB cases. The intention is to identify 
pitfalls that can be avoided to improve outcomes.  
Materials and Methods 
 
Retrospective analysis was undertaken of 100 consecutive patients with OSCC (CT/MRI T1-
T2 N0) treated between 2005-2013. The sentinel lymph node (SLN) technique followed 
standard protocol9. One-day (20-40 MBq) and two-day injection protocols (40-80 MBq) were 
used depending on resource availability. Static and dynamic imaging was performed in all 
patients with the addition of SPECT/CT in the final 26 cases (>2011).  
  
Surgery was performed using a blue dye optical tracer. Ipsilateral SLN’s retrieved at the time 
of surgery were either a) hot or blue or b) hot and blue, with firm nodes also being sampled 
and weaker contralateral nodes on SPECT/CT or hand-held gamma probe being disregarded.  
Evaluation consisted of an initial H&E section and, if negative, serial sections with H/E and, 
pan-keratin AE1/AE3 staining at 150 micron intervals5. If more than three nodes were 
harvested or there was a clear drop in gamma counts between nodes, the highest gamma count 
one was taken as the SLN and processed through the full protocol.  The remainder were 
processed by single section through the hilum and H&E staining. If the SLNs were negative it 
was assumed metastasis had not occurred and a watch and wait policy adopted. If positive, a 
level 1-4 completion neck dissection (CND) was undertaken. These CND’s were examined 
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by a single H&E hilum section, or from multiple 2mm cassette thickness slices if the node 
was thicker than 5mm (Figure 1). In preparation for this review all nodes harvested at SLNB 
were submitted for re-analysis. 
 
Contemporaneous data was stored in a bespoke database (InfoFlex v.5, CIMS Ltd. UK) 
consisting of demographics, performance status, lymphoscintigraphy findings, SLN status, 
SLNB complications and tumour status.  The type, site, date and subsequent treatment of any 
recurrences were noted.   
 
Failure was defined as recurrence at any site, death from disease, a FN SLNB, or failure to 
find a SLN. A FN SLNB was defined as a negative (-) SLNB with subsequent development 
of isolated neck squamous carcinoma metastasis.  
Statistical analysis  
 
R (R-Project, R Core Team) was utilised to perform the statistical analysis. Independent t-test 
was used to determine any statistical relationships between the patients’ demographics and 
their outcomes. The differences between the groups that developed complications and those 
that didn’t were compared with Chi-squared, Fisher’s exact tests and Welch’s two sample t-
test. Statistical probabilities that were less than 0.05 were considered significant. 
Results 
 
Details of 100 consecutive patients with OSCC (cT1 74%:  cT2 26%) N0 M0 were retrieved. 
In two cases lymphoscintigraphy failed to demonstrate a SLN but was effective in 98 patients, 
86 ipsilateral to the tumour, 10 bilateral, and 2 contralateral. On average, 2.5 SLN’s were 
retrieved per patient (range 1-6) with 19 patients having more than three excised, but in these 
patients only the hottest was subjected to the full histological SLNB protocol. 
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A total of 36 patients proved to have occult neck metastasis (26% of pT1 and 50% of pT2), 
33 were identified by SLNB and the remainder discovered as isolated recurrence during 
follow up (Table 1). The FN rate was therefore 8.33%. There were 12 deaths giving a crude 
survival of 88%. Eight of these were new primary tumours and were censored in the outcome 
analysis.  Four patients died from recurrence of the original carcinoma (disease specific 
survival of 96%). Three of these deaths may have been preventable (Table 2: Cases 3,7,8). 
Of the 33 +SLNB cases, 32 had CND and one received radiation alone. This was an error of 
medical assessment. After SLNB this patient was too frail for CND and had RT that failed to 
cure the disease (Table 2: Case 8). If it had been predicted the patient would not manage the 
two separate procedures, END would have been performed during the primary resection. 
Statistical analysis was performed on the pathological tumour factors with significant factors 
demonstrated in Table 3. 
Isolated neck recurrence  
 
Seven patients (excluding Case 8) developed isolated neck recurrence (Figure 1), four after 
+SLNB and ND and 3 after FN SLNB.  
 
The +SLNB cases (N=32) subsequently had a CND and in 78% (N=25) no further lymph 
node metastases were detected. Four (4/32) subsequently developed isolated neck recurrence. 
In two patients (Table 2: Cases 9, 10), this occurred in the un-operated contralateral neck and 
were rescued. In the other two (Table 2: Cases 6, 7), recurrence was ipsilateral and both died 
of disease.  For both there was reason for adjuvant therapy but it was not prescribed. In Case 
6 there was evidence of extra nodal spread and in Case 7, additional positive nodes at CND 
which were not detected by routine CND H&E evaluation. The micro-metastasis became 
evident only on serial section according to SLNB protocol of nodes retrieved at CND at the 
same neck level as the +SLN. These cases would consequently have been staged as N2 or N3 
disease and so eligible for post-operative radiotherapy (PORT).  
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Three patients (Table 2: Cases 3, 4, 5) with -SLNB had isolated neck recurrence (FN). In two, 
only one of the harvested SLN was examined and reported as negative. On re-evaluation, 
metastases were present in adjacent SLN’s not subjected to the full SLNB pathology protocol. 
The third FN (Case 5) was due to the shine-through phenomenon discussed later.    
Local recurrence  
 
One patient developed primary site recurrence (Table 2: Case 2). The original lesion was 
anterior FOM and the recurrence in the posterior FOM. This patient continued smoking with 
multiple episodes of non-attendance, finally re-attending with advanced disease. Pathological 
review showed inadequate excision margin of the primary tumour (1mm) and confirmed the -
SLNB status. Review found the Multidisciplinary Meeting did not recommend PORT or re-
excision due to poor patient compliance. 
Complications of Surgery 
 
Of 98 patients that underwent SLNB there were two complications directly attributable to the 
procedure – one superficial wound infection and one neck haematoma requiring return to 
theatre (no drain placed). General complications not directly attributable to the SLNB 
procedure consisted of a chest infection (managed with antibiotics) and a separate transient 
ischaemic attack two months post-surgery. Complications observed in patients returning for 
ND after a +SLNB has prompted a separate review that will be submitted soon.  
Cause of Error  
 
Imaging 
In two patients, drainage of tracer was inadequate. One with a floor-of-mouth (FOM) tumour 
(23 MBq on a one-day protocol), showed no drainage at 80 minutes post injection. The 
submental nodal fields were surgically explored but no SLN identified. This is possibly one 
of two examples of the shine-through effect with the radiation cloud at the injection site 
obscuring the adjacent SLN. 
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The second case related to a lesion of the anterior tongue. A two-day protocol was intended 
but a one day delivered (20 MBq tracer injected). At surgery, it was felt that there might be 
sufficient residual radiation to allow appropriate detection. At the initial lymphoscintigraphy 
two SLN’s were identified but these could not be found at surgery. Both necks were managed 
by observation and are without recurrence at five years. 
Shine-through is considered a risk of FOM radiotracer injection. In the present series, there 
were 12 patients with FOM carcinomas, one patient developed a new primary and died of 
disease, the remainder are disease free. One failed drainage and one FN have (Table 2:  Case 
5) been attributed to this cause. 
 
Errors of image interpretation lead to three recurrences’. SLN’s identified on gamma scan 
were intentionally not harvested due to the weak signal on SPECT/CT and hand-held gamma 
probe. This resulted in isolated neck recurrence, one ipsilateral and two contralateral (Table 2: 
Cases 4, 9, 10)  
Pathology  
In four cases, downgraded nodes clear of metastasis on routine H&E were found to contain 
micro-metastasis on subsequent serial sectioning (Table 2: Case 1, 3, 4, 7). Two of these 
patients succumbed to their disease.  No failures were ascribed to errors in pathological 
technique or interpretation.  
Discussion  
 
SLNB is a diagnostic test that identifies early metastasis, separating patients into a good 
prognostic group without metastasis and poor biological group with metastasis. In the former 
there is the option to de-escalate treatment and in the latter to do the opposite. In this series of 
patients staged by SLNB the disease specific survival was 96% despite a third having Stage 3 
disease. The authors acknowledge the lack of a comparable non-SLNB cohort in presenting 
survival data, this requires a large prospective randomised control trial. Nevertheless, the 
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SLNB process was successful and analysis has identified areas where technique 
improvements could further improve results. The overarching message is that even minor 
deviation from SLNB protocol can be detrimental to patient outcome. 
 
Lymphoscintigraphy failed in two cases (2%). In one (FOM), failure to image a SLN was 
probably due to the shine-through effect. This is where radiation uptake in submental SLN is 
obscured by the larger radiation dose at the FOM. The second failure was due to a protocol 
breach. A one-day radiation protocol was used for a two-day surgical case, meaning radiation 
had dissipated (half-life ~6 hrs) by the time of surgery. Consequently the SLN identified on 
the gamma scan could not be identified at the time of surgery. In retrospect the tracer dose 
should have been topped-up prior to surgery. The optimal radiation regime seems to be in the 
range of 15-20 MBq for a one day and 40-50 MBq for a two day SLNB protocol10.  
 
Lessons were learned in interpreting Gamma images. Usually in lateralised tumours there are 
one or two obvious hot areas in the ipsilateral neck with weaker signals in second order 
nodes. If there is drainage to the contralateral neck, the signal is invariably weaker. Prior to 
this analysis, we considered a weak signal as inconsequential but it appears these should not 
be ignored as they depict bone-fide drainage potentially containing metastases.  
The pathological preparation of the harvested SLN’s is expensive in time and technique. 
Early in our practice we believed that the hottest gamma count node would most likely 
contain metastasis. This assumption was incorrect.  Paradoxically when excess nodes are 
harvested (>3) it is usually because an obvious SLN can’t be identified. Selecting the correct 
SLN is an operator sensitive procedure, improving with experience. When unusually high 
numbers are harvested there should be careful discussion between nuclear medicine, 
pathology and surgeons to decide which, if not all, should be processed as a SLN. 
 
Two FN cases would have been eliminated as +SLN’s were harvested but not examined. This 
would have reduced the FN rate to 2.78%.  
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Another issue highlighted by this review is that when the +SLN is followed by a negative 
CND (78% of cases), there should be caution ascribing a pN1(sn) status. Isolated recurrence 
occurred in the ipsilateral neck after CND in two pN1(sn) patients. Standard single H&E 
section evaluation of nodes does not reliably identify all micro-metastases. When CND nodes 
taken from the same level as the +SLN were analysed by serial section, additional micro-
metastases were identified that had not been detected previously. The stage of disease was not 
N1(sn) but the equivalent of N2(sn) or N3(sn), categories not currently recognised in TNM8 
but probably qualifying for adjuvant therapy. Data from the SENT trial showed metastasis 
additional to the SLN are usually found in the same nodal basin as the +SLN11. After CND, a 
more detailed examination of nodes in the same level as the +SLN could improve staging. 
 
The impact of adverse histological features on outcome was typical of other series. The 
presence of increased depth of invasion, perinueural and sarcolemmal spread predicted for 
recurrent disease (Table 3) and were present in 53% +SLNB patients but only 17% of the -
SLNB.  However, of the 20 patients with these factors none developed local recurrence. The 
one patient who did was -SLNB and had close resection margins.  
  
A general perspective has held that SLNB may not be reliable when evaluating cancer in the 
anterior FOM due to ‘shine-through’12. Recurrent disease due to delayed diagnosis of neck 
disease through a FN report is difficult to rescue. Only 50% of cases can be successfully 
salvaged with maximal therapy (surgery + chemoradiotherapy). To eliminate this risk a 
submental dissection has been advocated for FOM cancers13 . The ability to identify “hot” 
nodes in the submental area may improve using Lymphoseek, a receptor mediated lymphatic 
tracer which clears the injection site and concentrates within nodes14. Additional marker use 
such as blue dye and fluorescence may also be advantageous15.  
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Conclusion 
Disease specific (96%) and disease free survival (92%) were excellent for a cohort of patients 
where 33% had stage 3 disease. The data shows that SLNB identified 92% of patients with 
occult metastasis, but if all harvested nodes had undergone serial section then 97% would 
have been identified giving a surgical FN rate of just 3%. Potential improvements in detection 
could have been achieved by harvesting gamma imaging faint contralateral nodes and 
ensuring all SLNB harvested nodes are evaluated by serial section through the SLNB 
protocol. Neck recurrence following CND proved fatal. If on routine H/E evaluation no 
additional nodal disease is detected, detailed analysis of CND nodes from the SLN nodal 
basin should be considered.  
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* Denotes treatment failure not ascribed to sentinel lymph node procedure 
** Denotes failure of SLN technique  
Figure 1 - Patient Treatment Pathway and Outcome 
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Table 1 – Disease Outcome by SLN Status 
Type of recurrence SLNB Negative (n=65) SLNB Positive (n=33) 
Local 0 0 
Local and Neck 0 0 
Neck only 3 4 
Local and Distant 0 0 
Local, Neck and Distant 0 1 
Total Recurrence 3 5 
Table 2 – Identified Errors Case Summaries 
Case 
Number 
Patient Factors Scintigraphy Surgery Pathology Site Outcome Recommendation 
-SLNB        
1   Multiple primaries 
Re-examination of additional nodes not 
treated as SLNB nodes identified 
micrometastasis 
Local - New 
Primary 
Alive no disease 
Put all samples 
through SLNB 
protocol 
2 
Poor compliance with 
smoking cessation and follow 
up  
  
4mm from nearest mucosal margin 
anteriorly. 1mm clearance at deep 
margin. Generalised field change. 
Local – ? New 
Primary 
Dead with disease Patient selection 
3    
Only 1 of 4 nodes went through SLNB 
protocol, further histology showed viable 
tumour cells in a remaining SLN 
Neck Dead with disease  
Put all samples 
through SLNB 
protocol 
4  
Re-review of imaging showed 2-3 less 
obvious ispilateral nodes deeper in 
tissue - aberration of depth 
 
Only 1 of 5 nodes went though SLNB 
protocol, with second stage analysis being 
sent to another unit. 
Neck Alive no disease 
Don’t ignore faint 
nodes. Put all 
samples through 
SLNB protocol 
5  
Shine through - very hot injection site 
obscuring Level 1B (site of 
recurrence) 
  Neck Alive no disease 
Routine harvest of 
submental nodes.  
+SLNB        
6    
Slides correctly reported. However SCC 
was extranodal within lymphatics and 
could account for extranodal recurrence 
Neck Dead with disease 
Detailed 
examination of CND 
nodes around SLN 
when only one SLNB 
positive 
7 
Recurrence at site of carotid 
bifurcation - inoperable 
 
Missed carotid 
node 
Additional micrometastases were present 
in CND that could have upstaged the neck 
- micrometastasis deposit small and away 
from hilum 
Neck Dead with disease 
Detailed 
examination of CND 
nodes around SLN 
when only one SLNB 
positive 
8 
Patient did not cope well with 
original surgery 
 
Should have had 
CND. Patient 
undertreated 
 
Local, Neck, 
Distant 
Dead with disease Patient selection 
9  
Pre op FNA was negative of 
contralateral nodes, contralateral 
nodes ignored at SLNB 
  Neck Alive no disease 
Don’t ignore faint 
nodes. 
10  
Hottest contralateral node taken, 
two faint delayed ipsilateral nodes 
due to depth ignored 
  Neck Alive no disease 
Don’t ignore faint 
nodes 
 
 
 
 
 
 
 
 
 
 
 
Table 3 - Significance of Primary Carcinoma Adverse Pathological Features by SLNB Result 
  Negative Positive  Welch Two sample t-test 
Depth of Invasion (mm) 3.59 7.52  <0.0005 
  Negative Positive Total Patients Fisher’s exact test 
Perineural 
Total 17 (61%) 11 (39%) 28 
0.0078 No 43 (74%) 15 (26%) 58 
Yes 2 (22%) 7 (78%) 9 
Sarcolemmal 
Total 18 (60%) 12 (40%) 30 
0.0065 No 40 (77%) 12 (23%) 52 
Yes 4 (31%) 9 (69%) 13 
